by Truveta Research | Jul 7, 2026 | Research
Adults over 50 showed two clear increases in measles titer testing in 2019 and 2025, concurrent with large outbreaks. Testing rates were generally higher in residents living in urban regions (compared to rural regions) and were highest among adults ages 50–59 for most...
by Truveta Research | Jul 6, 2026 | Featured research, Research
The rate of e-bike and e-scooter injury-related emergency department (ED) visits increased 7.5-fold among children and adolescents (<18 years) between 2023 and May 2026. More than one-third (35.4%) of patients were diagnosed with a head or neck injury. Traumatic...
by Truveta Research | Jun 29, 2026 | Research
Authors: Karen Gilbert Farrar, PhD ⊕Truveta, Inc, Bellevue, WA, Nina B Masters, PhD, MPH ⊕Truveta, Inc, Bellevue, WA, Duy Do, PhD ⊕Truveta, Inc, Bellevue, WA, Nicholas Stucky, MD, PhD ⊕Truveta, Inc, Bellevue, WA, Brianna M Cartwright, MS ⊕Truveta, Inc, Bellevue, WA...
by Truveta Research | Jun 26, 2026 | Research
Most patients (87.1%) with evidence of oral semaglutide for obesity had evidence of their first dose at 1.5 mg, consistent with the manufacturer-recommended starting dose. Timing of dose increases closely mirrored the recommended schedule, with dose increases...
by Truveta Research | Jun 18, 2026 | Research
Authors: Nina B Masters, PhD, MPH ⊕Truveta, Inc, Bellevue, WA, Karen Gilbert Farrar, PhD ⊕Truveta, Inc, Bellevue, WA, Duy Do, PhD ⊕Truveta, Inc, Bellevue, WA, Brianna M G Cartwright, MS ⊕Truveta, Inc, Bellevue, WA The Shingrix vaccine has been recommended for...
by Truveta Research | Jun 17, 2026 | Research
Prescribing of progesterone-containing hormone replacement therapy (HRT) more than quadrupled between 2018 and 2026. Women aged 45–54 years experienced the largest increase in prescribing, with rates increasing 488% between 2018 and 2026. By May 2026, 3% of women aged...
